

**Case report**

**Histiocytoid giant cellulitis-like Sweet's syndrome: case report and review of the literature**

**Jessica K. So MD, Casey A. Carlos MD PhD, Corey S. Frucht MD PhD, and Philip R. Cohen MD**

**Dermatology Online Journal 21 (3): 4**

**Department of Dermatology, University of California San Diego, San Diego**

**Correspondence:**

Philip R Cohen, MD  
10991 Twinleaf Court  
San Diego, CA 92131  
mitehead@gmail.com

---

**Abstract**

**Background:** Histiocytoid Sweet syndrome is an uncommon variant in which the dermal infiltrate is composed of mononuclear cells with a histiocytic appearance that represent immature myeloid cells. Giant cellulitis-like Sweet syndrome is a recently described variant characterized by relapsing widespread giant lesions.

**Purpose:** We report a unique patient with histiocytoid giant cellulitis-like Sweet syndrome and review the current literature on histiocytoid Sweet syndrome and giant cellulitis-like Sweet syndrome.

**Material and Methods:** We reviewed PubMed for the following terms and have reviewed the literature: histiocytoid, giant cellulitis-like, and Sweet syndrome.

**Results:** Six individuals, including our patient, have been reported with giant cellulitis-like Sweet syndrome; four had obesity, two had a hematologic malignancy, and one had breast cancer. Histiocytoid Sweet syndrome has been reported in association with autoimmune diseases, infection or inflammation, inflammatory bowel disease, malignancies, medications, and other conditions.

**Conclusions:** Histiocytoid Sweet syndrome is a rare variant of Sweet syndrome, often associated with malignancy. Giant cellulitis-like Sweet syndrome has been reported in six individuals; four of the patients were obese and three of the patients had an associated cancer. Our patient had histiocytoid giant cellulitis-like Sweet syndrome-associated myelodysplastic syndrome/myeloproliferative disorder. The diagnosis of histiocytoid Sweet syndrome or giant cellulitis-like Sweet syndrome should prompt the clinician to consider additional evaluation for a Sweet syndrome-associated malignancy.

**Keywords:** cellulitis, giant, histiocytoid, leukemia, Sweet, syndrome

**Introduction**

Giant cellulitis-like Sweet syndrome is a recently described form of acute febrile neutrophilic dermatosis [1]. Histiocytoid Sweet syndrome usually occurs in a paraneoplastic setting (Table 1) [2-26]. We describe a patient with histiocytoid giant cellulitis-like Sweet syndrome. We reviewed not only the previously reported patients with histiocytoid Sweet syndrome but also the previously described individuals with giant cellulitis-like Sweet syndrome.

**Table 1.** Characteristics of 64 patients with histiocytoid Sweet syndrome<sup>§\*</sup>

AS	Symptoms	WBC (cells/uL)	Assoc disease	Treatment	Response #	Ref
14M	Fever, Malaise, Abdominal pain, Hematochezia	18.85	CD	Mpredn	Excellent	6
21M	Fever, Weight loss	2.61	None	Predn	Excellent	15
39M	Conjunctivitis, Lymphadenitis	NL	HL	Chemotx, filgrastim	Good	9
57M	Arthralgias, Myalgias, Dysesthesias	NR	MDS	Pred, Chemotx, Col, Dap, CP, PP, MMF	Good	11
57M	Pain	NL	Parotitis	Mpredn	Excellent	10
58M	Fever, Arthralgias	29.5	CML	Pred, nilotinib	Good	12
65M	Fever	+	None	Pred, CS	Excellent	2
67M	Fever, Pruritus	NL	MM, Bort	Dexa, tCS, AH	Excellent	13
69M	None	NL	MM, Bort	Mpredn, tCS	Excellent	16
71M	Malaise, Dizziness	6.78	MDS	Pred, Thal	Excellent	14
72M	Fever	1.4	MDS	Pred	Excellent	22
75M	Fever, Arth	4.2	MDS, PAN	Pred	Good	18
75M	Fever, Arth	11.1	PNA	Mpredn	Excellent	24
5F	None	NL	SLE	HQ	Excellent	4C2
9F	Abdominal pain	NL	SLE	Mpredn, Dap	Excellent	4C1
29F	Fever, edema	12.4	Preg	tCS	Excellent	3
42F	Fever, Arth, Diarrhea, Abdominal pain, Hematochezia	NL	CD	Pred, AZA, Dap	Excellent	20
44F	Fever	1.1	MDS Decitabine	tCS	Excellent with relapses	17
44F	Fever, myalgias	1.2	Sinusitis TMP-SMX	None	Excellent	25
59F	Fever	NR	RA	Pred	Excellent	23
68F	Fever, Altered mental status	1	MDS, AML	tCS, AH	Good	21
70F	Fever, Pain	13.4	LC	HU, HHT	Poor	26
72F	Fever, Foot pain	73.5	MDS/MPD	tCS	Excellent	CR

Abbreviations:

AH=oral anti-histamine, AML=acute myelogenous leukemia, Ane=anemia, AS=age (years) and sex, AZA=azathioprine, Bort=bortezomib, CD=Crohn's disease, Chemotx= chemotherapy, CML=chronic myelogenous leukemia, col=colchicine, CP=cyclophosphamide, CR=current report, CS=cyclosporine, dap=dapsone, dexa=dexamethasone, F=female, HHT= homoharringtonine, HL=Hodgkin's lymphoma, HQ=hydroxychloroquine, HU=hydroxyurea, LC=leukemia cutis, M=male, MDS/MPD=myelodysplastic syndrome/myeloproliferative disorder, MM=multiple myeloma, MMF=mycophenolate mofetil, mpredn=methylprednisolone, NL=normal, NR=not reported, PAN=polyarteritis nodosa, PNA=pneumonia, PP=plasmapheresis, pred=prednisone, predn=prednisolone, Preg=pregnancy, RA=rheumatoid arthritis, Ref=reference, SLE=systemic lupus erythematosus, tCS=topical corticosteroid, Thal=thalidomide, Thr=thrombocytopenia, TMP-SMX=trimethoprim-sulfamethoxazole, +=elevated

<sup>S</sup>The site of skin lesions and (number of patients) for the 23 individuals reported separately were:

Location (# of patients)	[References]
Upper extremity (16)	[2, 3, 4 (case 1), 6, 9, 10, 11, 12, 14, 17, 18, 20, 21, 22, 24, 26]
Trunk (13)	[2, 11, 12, 13, 14, 15, 16, 18, 20, 22, 23, 25, CR]
Lower extremity (10)	[2, 4 (case 1), 6, 11, 14, 17, 20, 21, 26, CR]
Head (10)	[3, 4 (case 2), 9, 10, 12, 15, 17, 18, 24, 26]
Neck (6)	[3, 9, 11, 13, 14, 20]
Buttock (1)	[4 (case 1)]

\*These cases also include a series of 41 patients: 15 men and 26 women ranging in age from 29 years to 79 years. The site of skin lesions and (number of patients) were: trunk including abdomen and back (19), upper extremity including shoulder (19), hands including palms (12), lower extremity (7), face (2), feet including soles (1), and disseminated involvement of the whole body (1). Associated diseases included: B-chronic lymphocytic leukemia, breast carcinoma, chronic monocytic leukemia, conjunctivitis, erythema nodosum, eyelid edema, diabetes mellitus, immunosuppression, monoclonal gammopathy of undetermined significance, multiple myeloma, renal carcinoma, and ulcerative colitis [19].

<sup>#</sup>Excellent response defined as complete or near clearance of lesions, good response defined as lesion improvement without clearing, poor response defined as little or no response to treatment.



## Case synopsis

A 72-year-old woman with a history of leukocytosis with marked neutrophilia, thrombocytopenia, daily fevers, and foot pain presented for evaluation of a new rash. Her unexplained foot pain had been treated with oral prednisone and her symptoms improved at higher doses. The prednisone dose was tapered to 20 mg daily and continued at this dose for the last two years; it was difficult to further taper the daily dose because of her foot pain. Nonetheless, another attempt to taper her prednisone dose to 17.5 mg daily was made three weeks prior to onset of rash. Two weeks after the taper was initiated, she developed fever with temperatures as high as 39.8 degrees Centigrade.


Approximately three days prior to evaluation, the patient noticed the onset of a pink rash on her left upper leg that felt warm to the touch and slightly pruritic. Over the next few days, the rash extended in its involvement down the left leg and to the left flank. No preceding trauma occurred in the area and no topical treatments were attempted. No heating pads or cold packs were used. She had not experienced a recent streptococcal infection and she had no history of thyroid disease, lupus erythematosus, or inflammatory bowel disease.



Figure 1. Clinical photograph of the erythematous plaque on her left lateral thigh.








**Figure 2.** (a, b, c, d). Low (a), intermediate (b) and high (c, d) magnification views of the lesional skin biopsy. Prominent superficial dermal edema is noted, with a perivascular and interstitial inflammatory dermal infiltrate (a). Histiocytoid and immature granulocytic cells admixed with lymphocytes, eosinophils and occasional neutrophils are demonstrated on the higher magnification views (b, c, d) (hematoxylin and eosin: X4=a, X10=b, X40=c, X60=d).

Cutaneous exam revealed a 20 centimeter, non-tender, sharply demarcated erythematous plaque on her left lateral thigh containing a few scattered petechiae (Figure 1). Microscopic evaluation of the biopsy from the thigh plaque revealed a normal-appearing epidermis and prominent superficial dermal edema with a perivascular and interstitial inflammatory infiltrate of predominantly histiocytoid and immature granulocytic cells admixed with lymphocytes, eosinophils, and occasional neutrophils. Extravasated erythrocytes, hemosiderin-laden macrophages, and focal areas of vessel damage were also noted in the dermis (Figure 2).

Immunoperoxidase staining was performed to define the dermal infiltrate. CD68 staining (a marker for histiocytes) highlighted a majority of the interstitial cells (Figure 3). Myeloperoxidase staining (a marker for neutrophil granulocytes) also highlighted a majority of the interstitial cells, but with less intensity compared to CD68. CD117 staining (a marker for mast cells) highlighted rare interstitial cells.

Tissue cultures from the left thigh were negative for bacterial, fungal, and mycobacterial organisms. Blood cultures were also negative. Urine culture grew *Klebsiella oxytoca* and she was treated with ciprofloxacin.

Laboratory studies showed that her white blood cell count was markedly elevated at 73.5 cells/uL (range: 4-10 cells/uL), showing predominantly neutrophils (66%) with an absolute neutrophil count of 58.1 cells/uL (range: 1.6-7 cells/uL). She was also found to be anemic with a hemoglobin of 10.6 gm/dL (range: 11.2-15.7 gm/dL) and platelets were decreased to 46 (range: 140-370 cells/mL). Prothrombin time, partial thromboplastin time, and international normalized ratio were normal. Lactate dehydrogenase was elevated at 362 U/L (range: 135-214 U/L). Complete metabolic panel was normal, as was her thyroid-stimulating hormone (0.84 uIU/ml, range: 0.27-4.2 uIU/mL).



**Figure 3.** High magnification view show positive staining of the cells comprising the dermal infiltrate with CD68 (a histiocyte marker) (CD68: X40)

Correlation of clinical presentation, lesion morphology, and histologic features led to a diagnosis of giant cellulitis-like (based on lesion features) and histiocytoid (based on pathology findings) Sweet syndrome. Topical clobetasol dipropionate 0.05% ointment was used twice daily, with significant improvement of her dermatosis in two weeks.

During the hospitalization, a bone marrow biopsy was also performed, which showed a hyper-cellular marrow with trilineage hematopoiesis, decreased and dysplastic megakaryocytes, but no evidence for an increased or aberrant immature cell population. In the setting of pancytopenia and with identification of several common myeloid malignancy genes on somatic mutation analysis,

she was diagnosed with an unclassified myelodysplastic syndrome/myeloproliferative disorder. She was treated with decitabine, with resolution of leukocytosis and dramatic improvement of fevers and foot pain. At time of report, there has been no recurrence of her Sweet syndrome for eight months.

## Discussion

Sweet syndrome was described as an acute febrile neutrophilic dermatosis by Robert Douglas Sweet in 1964 [27]. The condition is characterized by the sudden onset of fever, leukocytosis, and tender, erythematous, well-demarcated papules and plaques. Sweet syndrome can be idiopathic. However, it can also follow an infection, including *Streptococcus* or *Yersinia*, or be associated with pregnancy, inflammatory bowel disease, medications, or malignancy [28].

Histology of lesional skin shows dense dermal neutrophilic infiltrates; vasculitis is usually minimal to absent. Classically, both the symptoms and skin lesions of Sweet syndrome have an excellent response to corticosteroids. Other treatments include colchicine, potassium iodide, and dapsone [27,28].

Clinical and histologic variants of Sweet syndrome have been described: neurologic Sweet syndrome [29], Sweet syndrome panniculitis [30], necrotizing Sweet syndrome [31] and Sweet syndrome concurrent with leukemia cutis [32]. More recently, histiocytoid Sweet syndrome and giant cellulitis-like Sweet syndrome have been reported [1,19].

Histiocytoid Sweet syndrome was initially described by Requena et al in 2005 [19]; subsequently, several additional observations of this unique variant of Sweet syndrome have been reported [5,7,25]. It is characterized by a dermal infiltrate composed of immature granulocytes that are histiocytic mononuclear cells, in contrast to the infiltrate of mature neutrophils typically seen in Sweet syndrome. Although the small cells of histiocytoid Sweet syndrome morphologically appear similar to neutrophils, they stain for CD15, CD43, CD45 (LCA), CD68, HAM56, lysozyme, and MAC 387, identifying a monocytic-histiocytic profile (Table 2) [19].

**Table 2.** Monocytic-histiocytic cell lineage antibody markers

Antibody	Specificity
CD15	Mature neutrophils, monocytes (promyelocytes)
CD43	Macrophages, myeloid cells
CD45 (LCA)	Granulocytes, macrophages, monocytes, all hematolymphoid cells
CD68	Basophils, macrophages, monocytes, myeloid precursors, neutrophils
HAM56	Macrophages, monocytes
Lysozyme	Granulocytes, histiocytes, macrophages, monocytes, myeloid cells
MAC 387	Granulocytes, monocytes, reactive macrophages

Abbreviations: LCA, leukocyte common antigen

Histiocytoid Sweet syndrome, to the best of our knowledge, has been described in 64 patients: 28 men and 37 women. Patients range in age from 5 years to 79 years (median: 59.5 years) at diagnosis; men range in age from 14 years to 79 years (median: 61.5 years) and women range in age from 5 years to 79 years (median: 55 years). The histiocytoid variant of Sweet syndrome has been associated with autoimmune diseases, malignancies, infections and inflammation, inflammatory bowel disease, medications, and other conditions (Table 3) [2-26]. The pathologic differential diagnosis of histiocytoid Sweet syndrome includes leukemia cutis and other inflammatory dermatoses histopathologically characterized by histiocytes interstitially arranged between dermal collagen bundles. Other diseases with this histologic picture include the interstitial type of granuloma annulare, interstitial granulomatous dermatitis with arthritis, and methotrexate-induced rheumatoid papules [19].

**Table 3.** Conditions and drugs associated with histiocytoid Sweet's syndrome

### Autoimmune diseases

Positive lupus erythematosus serologies [4,18,24]

Rheumatoid arthritis [23]

Systemic lupus erythematosus [4]

### Infections/inflammation

Conjunctivitis [19]

Methacillin-resistant staphylococcus aureus (pneumonia) [24]

Parotitis [10]

Sinusitis [25]

Inflammatory bowel disease

Crohn's disease [6,20]

Ulcerative colitis [19]

Malignancies

Acute myelogenous leukemia [21]

Breast carcinoma [19]

Chronic lymphocytic leukemia [19]

Chronic monocytic leukemia [19]

Chronic myelogenous leukemia [12]

Hodgkin's lymphoma [9]

Leukemia cutis (from acute myelomonocytic leukemia) [26]

Lymphoma [19]

Monoclonal gammopathy of undetermined significance [19]

Multiple myeloma [13,16,19]

Myelodysplastic syndrome [11,14,17,18,21,22]

Myelodysplastic syndrome/myeloproliferative disorder [current report]

Renal carcinoma [19]

Medications

Bortezomab [13,16]

Decitabine [17]

Trimethoprim-sulfamethoxazole [25]

Other conditions

Diabetes mellitus [19]

Erythema nodosum [19]

Eyelid edema [19]

Glomerulonephritis [4]

Hypertension [2]

Immunosuppression [19]

None [15, 19]

Polyarteritis nodosa [18]

Pregnancy [3]

Giant cellulitis-like Sweet syndrome is a morphologically distinctive clinical variant of Sweet syndrome characterized by relapsing widespread giant plaques. It was originally reported in three individuals with morbid obesity in 2013 [1]. Reports of two additional patients were published in 2014 [33,34]. To date, including our patient, giant cellulitis-like Sweet syndrome has been described in six individuals (Table 4) [1,33,34].

**Table 4.** Characteristics of patients with giant cellulitis-like Sweet's syndrome [\*]

AS	Symptoms	WBC (cells/uL)	Other labs	Assoc dis	Tx	Response	Ref
62M	Fever Malaise	10.6 +	ANA – CRP +	Ob MM	Amox Pred	No effect from antibiotics; good response from oral prednisone	1C1
48F	Fever Malaise	24 +	CRP +	Ob	Pred	Good control	1C2
54F	Fever	4.1	Creat + TC –	Ob PBC Si	Pred	Excellent	33
60F^	Fever	10.3	TC –	–	Col Pred Dap	Response, but recurrence on colchicine and prednisone; excellent response to dapsone and	34

						prednisone	
68F	Fever Malaise	11.3 +	CRP + TC –	Br Ob	Surg Top	Transient improvement then recurrence with topical corticosteroid; remission after surgical treatment of breast carcinoma	1C3
72F	Fever Foot pain	73.5 +	LDH + TC –	MDS/ MPD	Top	Excellent	CR

Abbreviations: AS=age (in years) and sex, Amox=amoxicillin/clavulanic acid, ANA=antinuclear antibody, Assoc dis=associated disease, Br=breast carcinoma, Col=colchicine, CR=current report, CRP=C-reactive protein, Creat=serum creatinine, Dap=dapsone, F=female, LDH=lactate dehydrogenase, M=male, MDS/MPD=myelodysplastic/myeloproliferative disorder, MM=multiple myeloma, Ob=obesity, PBC=primary biliary cirrhosis, Pred=prednisone, Ref=reference, Si=sicca syndrome, Surg=surgical treatment of breast carcinoma, TC=tissue culture, Top=topical corticosteroid, Tx=treatment, WBC=white blood cell, ^=patient was in her "60's", +=elevated, -=negative.

\* The site of skin lesions and (number of patients) were:

Location (# of patients)	[References]
Lower extremity (6)	[1 (cases 1, 2, and 3), 33, 34, CR]
Trunk (5)	[1 (cases 1 and 2), 33, 34, CR]
Buttock (3)	[1 (cases 1 and 2), 33]
Upper extremity (2)	[1 (case 2), 33]
Head and neck (1)	[33]

Giant cellulitis-like Sweet syndrome has been observed in five women and one man. The median age at diagnosis was 62 years, ranging from 48 years to 68 years. The skin lesions most commonly occurred on the upper leg and buttocks. Four of the six patients were obese and three of the six patients had an associated malignancy: hematologic dyscrasia (multiple myeloma or myelodysplastic syndrome/myeloproliferative disorder), and breast cancer. The differential diagnosis of giant cellulitis-like Sweet syndrome includes not only cellulitis and other infections, but also periodic syndromes such as familial Mediterranean fever. Therefore, biopsy for histology, as well as tissue cultures, should be considered.

## Conclusion

Histiocytoid Sweet syndrome is an uncommon variant in which histiocyte-like immature myeloid cells compose the dermal infiltrate. Giant cellulitis-like Sweet syndrome is a rare clinical variant characterized by relapsing widespread giant plaques on the leg and buttocks of middle-aged women. Our patient is unique in having both of these unusual variants. When the diagnosis of histiocytoid Sweet syndrome is entertained, leukemia cutis should be excluded and when the diagnosis of giant cellulitis-like Sweet syndrome is suspected, biopsy for histology and tissue culture should be considered. .

## Reference

1. Surovy AM, Pelivani N, Hegyi I, Buettiker U, Beltraminelli H, Borradori L. Giant cellulitis-like Sweet Syndrome, a new variant of neutrophilic dermatosis. *JAMA Dermatol.* 2013 Jan;149(1):79-83. [PMID = 23324762]
2. Apalla Z, Kanatli L, Sotiriou E, Manousari A, Papagarifallou I, Calonje E. Histiocytoid Sweet syndrome. *Clin Exp Dermatol.* 2011 Jul;36(5):562-3. [PMID = 21679369]
3. Bilgili SG, Karadag AS, Calka O, Bulut G. Histiocytoid Sweet syndrome. *Int J Dermatol.* 2014 Feb;53(2):e80-2. [PMID = 23330976]
4. Camarillo D, McCalmont TH, Frieden IJ, Gilliam AE. Two pediatric cases of nonbullous histiocytoid neutrophilic dermatitis presenting as a cutaneous manifestation of lupus erythematosus. *Arch Dermatol.* 2008 Nov;144(11):1495-8. [PMID = 19015425]
5. Chow S, Pasternak S, Green P, Tremaine R, Reardon M, Murray S, Northgrave S, Walsh N. Histiocytoid neutrophilic dermatoses and panniculitides: variations on a theme. *Am J Dermatopathol.* 2007 Aug;29(4):334-41. [PMID = 17667165]
6. Fernández-Torres RM, Castro S, Moreno A, Alvarez R, Fonseca E. Subcutaneous histiocytoid sweet syndrome associated with crohn disease in an adolescent. *Case Rep Dermatol Med.* 2014;2014:954254. [PMID = 24839565]
7. Gerami P, Guitart J. Panniculitis with histiocytoid/immature neutrophils is not limited to histiocytoid panniculitic Sweet syndrome. *Am J Dermatopathol.* 2007 Dec;29(6):596. [PMID = 18032966]
8. Heymann WR. Histiocytoid Sweet syndrome. *J Am Acad Dermatol.* 2009 Oct;61(4):693-4. [PMID = 19751884]



9. Hünermund A, Wendel AM, Geissinger E, Bröcker EB, Stoevesandt J. Typically atypical: histiocytoid Sweet syndrome, associated with malignancy. *J Dtsch Dermatol Ges*. 2011 Sep;9(9):666-9. [PMID = 21884413]
10. Jo MS, Lim YB, Shin HK, Choe J, Seul JH, Jang TJ. A Case Report of Sweet's Syndrome with Parotitis. *Arch Plast Surg*. 2012 Jan;39(1):59-62. [PMID = 22783494]
11. Kaiser R, Connolly K, Linker C, Maldonado J, Fye K. Stem cell transplant for myelodysplastic syndrome-associated histiocytoid Sweet's syndrome in a patient with arthritis and myalgias. *Arthritis Rheum*. 2008 Dec 15;59(12):1832-4. [PMID = 19035416]
12. Kasuya A, Fujiyama T, Hashizume H, Inuzuka M, Tokura Y. Histiocytoid Sweet's syndrome associated with t(9;22)(q34;q11)-positive chronic myelogenous leukemia: immature granulocytic origin of histiocytic cells. *Int J Dermatol*. 2013 Dec;52(12):1577-9. [PMID = 24261731]
13. Kim JS, Roh HS, Lee JW, Lee MW, Yu HJ. Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma. *Int J Dermatol*. 2012 Dec;51(12):1491-3. [PMID = 22998496]
14. Lin J, Zhang Q, Chen M. Subcutaneous histiocytoid Sweet's syndrome in a patient associated with myelodysplastic syndrome-refractory anemia. *J Dermatol*. 2012 Jan;39(1):99-101. [PMID = 22007966]
15. Liu CI, Hsiao CH, Wu JT, Tsai TF. Sweet syndrome with histiocytoid infiltrate and neutropenia: A rare combination. *J Am Acad Dermatol* 2009;61:882-4. [PMID = 19733935]
16. Murase JE, Wu JJ, Theate I, Cole GW, Barr RJ, Dyson SW. Bortezomib-induced histiocytoid Sweet syndrome. *J Am Acad Dermatol*. 2009 Mar;60(3):496-7. [PMID = 19231647]
17. Park JY, Park JS, Kim YC. Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome. *Eur J Dermatol*. 2012 Nov-Dec;22(6):811-2. [PMID = 23178879]
18. Pinal-Fernandez I, Ferrer Fabrega B, Ramentol Sintas M, Solans Laque R. Histiocytoid Sweet syndrome and cutaneous polyarteritis nodosa secondary to myelodysplastic syndrome. *Int J Rheum Dis*. 2013 Dec;16(6):777-9. [PMID = 24382288]
19. Requena L, Kutzner H, Palmedo G, Pascual M, Fernández-Herrera J, Fraga J, García-Díez A, Yus ES. Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. *Arch Dermatol*. 2005 Jul;141(7):834-42. [PMID = 16027297]
20. Spencer B, Nanavati A, Greene J, Butler DF. Dapsone-responsive histiocytoid Sweet's syndrome associated with Crohn's disease. *J Am Acad Dermatol*. 2008 Aug;59(2 Suppl 1):S58-60. [PMID = 18625393]
21. Srisuttiyakorn C, Reeve J, Reddy S, Imaeda S, Lazova R. Subcutaneous histiocytoid Sweet's syndrome in a patient with myelodysplastic syndrome and acute myeloblastic leukemia. *J Cutan Pathol*. 2014 May;41(5):475-9. [PMID = 24877196]
22. Ten Oever J, Kuijper PH, Kuijpers AL, Dercksen MW, Vreugdenhil G. Complete remission of MDS RAEB following immunosuppressive treatment in a patient with Sweet's syndrome. *Neth J Med*. 2009 Sep;67(8):347-50. [PMID = 19767665]
23. Wang T, Liu Y, Zheng H. Histiocytoid Sweet's syndrome associated with rheumatoid arthritis and pleuritis. *Chin Med J (Engl)*. 2014;127(7):1396. [PMID = 24709205]
24. Wilson TC, Stone MS, Swick BL. Histiocytoid Sweet syndrome with haloed myeloid cells masquerading as a cryptococcal infection. *Am J Dermatopathol* 2014;36:264–269. [PMID = 23739245]
25. Wu AJ, Rodgers T, Fullen DR. Drug-associated histiocytoid Sweet's syndrome: a true neutrophilic maturation arrest variant. *J Cutan Pathol*. 2008 Feb;35(2):220-4. [PMID = 18300386]
26. Zhenying Z, Xiaoming L, Yongjun P, Shixin H. A case of leukemia cutis presenting as histiocytoid Sweet's syndrome. *Int J Dermatol*. 2013 Nov;52(11):1338-41. [PMID = 23451723]
27. Burrall B: Sweet's syndrome (acute febrile neutrophilic dermatosis). *Dermatol Online J* 1999;5(1):8. [PMID = 10673451]
28. Anzalone CL, Cohen PR. Acute febrile neutrophilic dermatosis (Sweet's syndrome). *Curr Opin Hematol*. 2013 Jan;20(1):26-35. [PMID = 23207661]
29. Nobeyama Y, Kamide R. Sweet's syndrome with neurologic manifestation: case report and literature review. *Int J Dermatol*. 2003 Jun;42(6):438-43. [PMID = 12786869]
30. Cohen PR. Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis. *J Am Acad Dermatol*. 2005 May;52(5):927-8. [PMID = 15858502]
31. Kroshinsky D, Alloo A, Rothschild B, Cummins J, Tan J, Montecino R, Hoang MP, Duncan L, Mihm M, Sepehr A. Necrotizing Sweet syndrome: a new variant of neutrophilic dermatosis mimicking necrotizing fasciitis. *J Am Acad Dermatol*. 2012 Nov;67(5):945-54. [PMID = 22445215]
32. del Pozo J, Martínez W, Pazos JM, Yebra-Pimentel MT, García Silva J, Fonseca E. Concurrent Sweet's syndrome and leukemia cutis in patients with myeloid disorders. *Int J Dermatol*. 2005 Aug;44(8):677-80. [PMID = 16101872]
33. Kaminska EC, Nwaneshiudu AI, Ruiz de Luzuriaga A, Tsoukas M, Bolotin D. Giant cellulitis-like Sweet syndrome in the setting of autoimmune disease. *J Am Acad Dermatol*. 2014 Sep;71(3):e94-5. [PMID = 25128145]
34. Koketsu H, Ricotti C, Kerdel FA. Treatment of giant cellulitis-like Sweet syndrome with dapsone. *JAMA Dermatol*. 2014 Apr;150(4):457-9. [PMID = 24577134]